Due to the asymptomatic nature of early hepatocellular carcinoma (HCC), HCC can only be evaluated by some early biomarkers in the patient’s body, such as serum α-fetoprotein (AFP) (2), Glypican-3 (GPC3) (3), and tumor-associated antigens (TAAs) (4). This evidence concerns the gene GPC3 and hepatocellular carcinoma.